Reuters logo
BRIEF-Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent
April 25, 2017 / 12:26 PM / 5 months ago

BRIEF-Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent

April 25 (Reuters) - Catabasis Pharmaceuticals Inc

* Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent in duchenne muscular dystrophy at the American Academy of Neurology 69th annual meeting

* Catabasis Pharmaceuticals Inc - Part C interim results to be announced in Q3 2017 for MoveDMD trial for edasalonexent

* Catabasis Pharmaceuticals - prespecified analysis of Part B data from MoveDMD trial shows improvement in rates of change across 5 functional assessments

* Catabasis Pharmaceuticals Inc - consistent with Part A, there were no safety signals and edasalonexent was well tolerated in Part B of trial

* Catabasis Pharmaceuticals - there were no treatment-related serious adverse events, no drug discontinuations and no dose reductions in Part B of trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below